Synchroneuron Secures $20,000,000 Series B Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ef7e4ef9-1893-44d1-9f14-7846c43eb632
Date
7/2/2014
Company Name
Synchroneuron
Mailing Address
130 Tobey Garden Street Duxbury, MA 02332 USA
Company Description
Synchroneuron Inc., a Waltham, Mass.-based biopharmaceutical company that develops new therapies for tardive dyskinesia (TD) and other related movement disorders.
Website
http://www.synchroneuron.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Series B
Proceeds Purposes
This funding supports the continued development of SNC-102, a new formulation of acamprosate calcium currently being studied in a Phase 2 trial to treat moderate-to-severe tardive dyskinesia (TD).
M&A Terms
Venture Investor